SWOT Analysis for Neogenomics Inc.

Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Company reducing Debt
Increasing Revenue every Quarter for the past 4 Quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Increasing profits every quarter for the past 3 quarters
Stock with Low PE (PE < = 10)

Promoter decreasing their shareholding
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Low DVM Stocks - Stocks to Exercise Caution On
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Risky Value (DVM)
Low durability companies
Top Losers
Declining Net Cash Flow : Companies not able to generate net cash
Book Value Per Share deteriorating for last 2 years
Weak performer : Stock lost more than 20% in 1 month
Weak Momentum: Price below Short, Medium and Long Term Averages
RSI indicating price weakness
Near 52 Week Low
Top Losers
Stocks Underperforming their Industry Price Change in the Quarter